Amsterdam Molecular Therapeutics appoints chief medical officer

Dutch human gene therapy specialist hires Carlos Camozzi

Amsterdam Molecular Therapeutics (AMT), a Netherlands-based human gene therapy specialist, has appointed Carlos Camozzi as chief medical officer. He has more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency and US Food and Drug Administration.

Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.

From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.

Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.

You may also like

Research & Development

AMT receives €1.1m funding as part of EU consortium grant

For Acute Intermittent Porphyria (AIP) gene therapy
Manufacturing

AMT to supply manufacturing for gene therapy product

For a rare genetic disorder in children
Research & Development

Reacta Healthcare announces expansion into Asia-Pacific and appoints Professor Gary Wing-Kin Wong to advisory board

Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint
Research & Development

BioDuro and CTI Technology partner to push forward preclinical drug development

The duo will combine their manufacturing experience and analytical capabilities to build an integrated platform spanning all the way from drug discovery to IND submission to accelerate the drug development path for clients
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Subscribe now